Hepatitis b carriers to apply for drug costs were rejected publicly, or to prosecute the NDRC | NDRC | hepatitis b carriers _ news

Newspaper Chief Jiang Gewei text/graph

The month, Lei Chuang persons more than 10 employees, such as hepatitis b (referring to carriers or their relatives, the same below), sending information to the national development and Reform Commission open letter, asking for a public cost of hepatitis b drug produced by Glaxo Smith Kline, promotes hepatitis b drug prices. On September 29, the newspaper reported this case in detail (see September 29, Glaxo Smith Kline bribe-induced high medicine price 15 application cost public medicine for hepatitis b carriers).

Then, as involving trade secrets by the NDRC, applications for disclosure of all the information made no public response.

On December 9, Lei Chuang 8 provinces total 10 hepatitis b people with the NDRC does not expose a Glaxo SmithKline 100 million carriers of hepatitis b hepatitis b drug costs will affect the public interest, by reason of violation of regulations on the disclosure of Government information, brought against the national development and Reform Commission on administrative reconsideration, request renewed information public response by the national development and Reform Commission, and Glaxo SmithKline hepatitis b drug costs.

　　Apply for information disclosure

In order to boost drug sales, Glaxo Smith Kline channeling money for staff, caused by the hepatitis b drug prices artificially high, and the penalty imposed by the Court of 3 billion yuan, and several former executives were sentenced to prison.

Media reported that Glaxo SmithKline "star product", China's widespread use of lamivudine in hepatitis b patients (generic lamivudine) and Hepsera (generic name adefovir dipivoxil) is also included in their high priced products. The companies selling drugs at inflated prices, "bribed marketing costs accounting for price 30%", its real bribe cost borne by patients and the public finances, including the hepatitis b, lamivudine, adefovir dipivoxil, all of them have been incorporated into the national health care directories.

On July 2, 2013, General Office of State development and Reform Commission issued notice of a survey on the costs and prices of some companies, including Glaxo Smith Kline (Tianjin) limited of 60 companies will come under the State development and Reform Commission, price surveys, and Glaxo Smith Kline (Tianjin) Limited is the penalty imposed by the Court in Changsha 3 billion yuan of Glaxo SmithKline (China) investment company affiliated companies.

In late September, Ray into contact more than more than 10 hepatitis b carriers nationwide, according to the Government information disclosure Ordinance, respectively, to the national development and Reform Commission mailed information letters of application, "application for Glaxo Smith Kline (Tianjin) limited cost of hepatitis b drug lamivudine and adefovir dipivoxil for survey results in the price survey. ”

　　Apply for administrative reconsideration

On October 13, Lei Chuang received a disclosure written reply of the national development and Reform Commission.

Reply says "due to your disclosure of Glaxo SmithKline's lamivudine and adefovir dipivoxil cost information relating to the company trade secrets, for comments, the company does not agree to open it. Therefore, I appointed under the provisions of article 23rd of the regulations on disclosure of Government information, and will not be made public. "

Subsequently, the country hepatitis b also received the Commission's reply, reply is basically the same. Lei Chuang the information to the national development and Reform Commission publicly dissatisfied with the reply, that hepatitis b drug Commission refused to disclose the cost, in violation of regulations on the disclosure of Government information the 23rd of the rules.

The Government information disclosure Ordinance, article 23rd: the Administration finds that the disclosure of Government information relating to trade secrets, personal privacy, disclosure may prejudice the legitimate rights and interests of third parties, and shall give a written request for third opinion; third-party does not agree to open, shall not be disclosed. However, the authorities do not think the public may have a significant impact on the public interest, should be made public, and decided to open Government with written notification of the reasons for any information to third parties.

"This is a public event, does not involve trade secrets. National development and Reform Commission's attitude was being fobbed off national hepatitis b carriers. "Lei Chuang believes that because the information is not open already and will still have a major negative impact on the public interest, according to the Government information disclosure Bill within the scope shall be made public.

Accordingly, on December 9, Lei Chuang 8 provinces total 10 hepatitis b carriers or their relatives, sent out the administrative reconsideration, filed administrative review of the national development and Reform Commission, requiring renewed information public response by the national development and Reform Commission, and Glaxo SmithKline hepatitis b drug costs.

"If the administrative reconsideration decision not to support the request, and also the prosecution of national development and Reform Commission. "Lei Chuang said.

Law weekly